Octreotide Ratiopharm (Octreotide Acetate)

Octreotide acetate, the active ingredient in Octreotide Ratiopham, is a somatostatin analog presented as a sterile solution for intramuscular and intravenous use. It reduces excessive hormone secretion in conditions such as acromegaly, carcinoid syndrome, and VIP‑secreting tumors, and is employed off‑label to lower the risk of postoperative pancreatic fistula formation. It is indicated for adult patients requiring hormone control.

GNH USA supplies Octreotide Ratiopham as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring reliable quality and regulatory compliance.

Octreotide acetate is used to manage disorders driven by excess hormone secretion within the endocrine and neuroendocrine pathways.

- Acromegaly: reduces excessive growth hormone secretion, leading to normalization of IGF‑1 concentrations and improvement of disease‑related symptoms. - Carcinoid syndrome: decreases serotonin‑mediated flushing and diarrhea, providing symptomatic relief in patients with neuroendocrine tumors. - VIP‑secreting tumors (VIPoma): controls severe watery diarrhea, electrolyte loss and abdominal cramping by suppressing vasoactive intestinal peptide release.

Octreotide acetate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Abdominal discomfort - Diarrhea - Injection site pain

Serious or Rare Side Effects: - Pancreatitis - Severe hypoglycemia - Gallbladder disease (cholecystitis or gallstones) - Anaphylactic reactions

Octreotide acetate requires careful monitoring in several clinical situations. - Renal impairment: monitor renal function and adjust dosing if necessary. - Hepatic dysfunction: use with caution; monitor liver enzymes. - Gallbladder disease: patients with existing gallstones may develop complications; monitor. - Blood glucose: observe for hyperglycemia or hypoglycemia, especially in diabetic patients. - Pregnancy and lactation: prescribe only when benefit outweighs potential risk to fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Octreotide acetate can interact with other medicines, requiring attention to avoid or monitor co‑administration.

Major Interactions (Avoid): - Concurrent use of other somatostatin analogues: may lead to additive hormonal suppression. - Long‑acting octreotide formulations: avoid simultaneous administration. - Diazoxide: can antagonize octreotide’s inhibitory effect on insulin secretion.

Moderate Interactions (Monitor Closely): - Antidiabetic agents (insulin, sulfonylureas): monitor for hypoglycemia. - Antiplatelet or anticoagulant therapy: increased risk of gallbladder sludge formation. - Radiolabeled peptide therapies: may alter distribution of octreotide.